Clinical Study

Testing The Effect Of Adding Abiraterone Acetate And Enzalutamide To Metastatic Hormone Refractory Prostate Cancer, When Compared To Enzalutamide Alon

Posted Date: May 15, 2019

  • Investigator: Nilesh Patil
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to compare the effects, good and/or bad, of abiraterone, prednisone and enzalutamide with enzalutamide alone on patients and their cancer to find out which is better. Doctors are uncertain about which way is the best way to treat castration resistant prostate cancer (CRP

Criteria:

To Be Eligible To Participate, Patients Must Have Prostate Cancer That Has Spread And Has Not Respon

Keywords:

Abiraterone, Metastatic Prostate , Enzalutamide, Cancer, A031201

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.